Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAT2A | P31153 | 3/20 | 0.35 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.31 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | CCND2 | P30279 | 1/20 | 0.31 |
| ▸ | CCND3 | P30281 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2953701 | 0.88 | KDR (0.36) | SMN1; SMN2LMNAMAT2AALDH1A1GAA | |
| SCHEMBL2949354 | 0.84 | MAPK14 (0.34) | MAT2ABCAT1PIK3CDPIK3R1ADORA2A | |
| SCHEMBL2959762 | 0.81 | CDK4 (0.38) | SMN1; SMN2CDK4CCND1CCND2CCND3 | |
| SCHEMBL2956501 | 0.81 | ALDH1A1 (0.37) | SMN1; SMN2LMNAMAT2AALDH1A1GAA | |
| SCHEMBL2954060 | 0.80 | NPC1 (0.37) | SMN1; SMN2LMNAMAT2AALDH1A1GAA | |
| SCHEMBL2956795 | 0.80 | MAP2K1 (0.34) | LMNAMAT2ABCAT1CDK4CCND1 | |
| SCHEMBL2960274 | 0.80 | G6PD (0.30) | — | |
| SCHEMBL2957270 | 0.79 | CXCR2 (0.39) | SMN1; SMN2LMNACDK4CCND1CCND2 | |
| SCHEMBL2958483 | 0.77 | CYP3A4 (0.39) | LMNAALDH1A1 | |
| SCHEMBL2955895 | 0.77 | MEN1 (0.35) | SMN1; SMN2LMNACDK4CCND1CCND2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763729-B2 | Bicyclic heteroaromatic derivatives | UCB PHARMA S.A. (BE) | 2010-07-27 | — | — | US | claimed |
| US-20090042877-A1 | Bicyclic Heteroaromatic Derivatives | CELLTECH R&D LIMITED (GB) | 2009-02-12 | — | — | US | claimed |
| US-7423047-B2 | Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2008-09-09 | — | — | US | claimed |
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | UCB PHARMA S.A. (BE) | 2006-01-05 | — | — | US | claimed |
| US-7763729-B2 | Bicyclic heteroaromatic derivatives | UCB PHARMA S.A. (BE) | 2010-07-27 | — | — | US | disclosed |
| US-20090042877-A1 | Bicyclic Heteroaromatic Derivatives | CELLTECH R&D LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-7423047-B2 | Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2008-09-09 | — | — | US | disclosed |
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | UCB PHARMA S.A. (BE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | MAPK1, CNKSR1, ALK | SMN1; SMN2 3637/4885LMNA 3193/4885MAT2A 2474/4885 |
| US-20090042877-A1 | Bicyclic Heteroaromatic Derivatives | MAPK1, CNKSR1, CBR1 | SMN1; SMN2 3472/4885LMNA 3052/4885MAT2A 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.